Publicaciones en las que colabora con Francisco Marín Ortuño (93)

2023

  1. Adverse Clinical Outcomes and Associated Predictors in Rivaroxaban-Treated Atrial Fibrillation Patients With Renal Impairment

    American Journal of Cardiology, Vol. 203, pp. 122-127

  2. Cohort profile: the ESC EURObservational Research Programme Non-ST-segment elevation myocardial infraction (NSTEMI) Registry

    European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 9, Núm. 1, pp. 8-15

  3. Effect of Routine Invasive vs Conservative Strategy in Older Adults With Frailty and Non-ST-Segment Elevation Acute Myocardial Infarction: A Randomized Clinical Trial

    JAMA Internal Medicine, Vol. 183, Núm. 5, pp. 407-415

  4. Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban

    Journal of comparative effectiveness research, Vol. 12, Núm. 3, pp. e220049

  5. Post-COVID-19 Symptoms and Heart Disease: Incidence, Prognostic Factors, Outcomes and Vaccination: Results from a Multi-Center International Prospective Registry (HOPE 2)

    Journal of Clinical Medicine, Vol. 12, Núm. 2

  6. Post-COVID-19 syndrome and diabetes mellitus: a propensity-matched analysis of the International HOPE-II COVID-19 Registry

    Frontiers in Endocrinology, Vol. 14

  7. Prospective observational registry of perioperative and periprocedural management of antithrombotic therapy in “real world”: the REQXAA study

    Revista Espanola de Cardiologia, Vol. 76, Núm. 9, pp. 729-738

  8. Survival after Invasive or Conservative Management of Stable Coronary Disease

    Circulation, Vol. 147, Núm. 1, pp. 8-19

2022

  1. A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction

    Circulation, Vol. 146, Núm. 16, pp. 1196-1206

  2. Aspirin Therapy on Prophylactic Anticoagulation for Patients Hospitalized With COVID-19: A Propensity Score-Matched Cohort Analysis of the HOPE-COVID-19 Registry

    Journal of the American Heart Association, Vol. 11, Núm. 13

  3. Chronic Oral Anticoagulation Therapy and Prognosis of Patients Admitted to Hospital for COVID-19: Insights from the HOPE COVID-19 Registry

    International Journal of Clinical Practice, Vol. 2022

  4. Current trends on antithrombotic therapy

    REC: CardioClinics

  5. Outcomes and predictive value of the 2MACE score in patients with atrial fibrillation treated with rivaroxaban in a prospective, multicenter observational study: The EMIR study

    Cardiology Journal, Vol. 29, Núm. 4, pp. 601-609

  6. Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry

    European heart journal. Cardiovascular pharmacotherapy, Vol. 9, Núm. 1, pp. 38-46

  7. Rivaroxaban for the prevention of outcomes in patients with atrial fibrillation in clinical practice: an indirect comparison of national and international registries

    Journal of comparative effectiveness research, Vol. 11, Núm. 16, pp. 1173-1184

  8. Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR study

    European Journal of Clinical Investigation